Table 1.
Cohort composition after excluding study failures. Medication/comorbidity surveys were not completed by 5 participants from the autism spectrum disorder cohort.
| Demographic and phenotypic characteristics | Autism spectrum disorder (N=16) | Neurotypical controls (N=17) | |
| Gender, n (%) |
|
|
|
|
|
Males | 13 (81) | 9 (53) |
|
|
Females | 3 (19) | 8 (47) |
| Age (years), mean (SD; range) | 12.13 (3.31; 6-17) | 11.53 (2.48; 8-17) | |
| Social Communication Questionnaire score, mean (SD; range) | 18.86 (6.43; 7-31) | 1.82 (1.07; 0-4) | |
| Abbreviated Battery Intelligence Quotient standard score, mean (SD; range) | 102.75 (19.54; 55-133) | 108.94 (9.58; 91-129) | |
| Social Responsiveness Scale Total score, mean (SD; range) | 78.85 (11.13; 58->90) | 44.41 (8.11; 36-64) | |
| Comorbid psychological conditions, n (%) |
|
|
|
|
|
Anxiety disorder/depression | 1 (9)a | 0 (0) |
|
|
Attention-deficit/hyperactivity disorder | 1 (9)a | 1 (5) |
| Current medication, n (%) |
|
|
|
|
|
Methylphenidate | 3 (27)a | 0 (0) |
|
|
Arginine vasopressin | 1 (9)a | 0 (0) |
|
|
Guanfacine extended release | 1 (9)a | 0 (0) |
|
|
Sertraline | 2 (18)a | 0 (0) |
|
|
Carbamazepine | 1 (9)a | 0 (0) |
|
|
Aripiprazole | 1 (9)a | 0 (0) |
|
|
Dexmethylphenidate | 1 (9)a | 0 (0) |
|
|
Allergy medication (unspecified) | 0 (0)a | 1 (5) |
|
|
Other (unspecified) | 0 (0)a | 1 (5) |
|
|
No medication | 4 (36)a | 15 (88) |
aN=11.